Myogen to Announce 2006 First Quarter Results on May 8, 2006

Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company
focused on the discovery, development and commercialization of small
molecule therapeutics for the treatment of cardiovascular disorders,
today announced that it will report 2006 first quarter results the
morning of Monday, May 8, 2006.
   J. William Freytag, President and CEO, and other members of
Myogen's senior management will provide a company update and discuss
results via webcast and conference call on Monday, May 8, 2006, at
8:00 a.m. Eastern. To access the live webcast, please log on to the
company's website at www.myogen.com and go to the Investor Relations
section. Alternatively, callers may participate in the conference call
by dialing 800-240-2430 (domestic) or 303-205-0033 (international).
Webcast and telephone replays of the conference call will be available
approximately two hours after the completion of the call through
Friday, May 26, 2006. Callers can access the replay by dialing
800-405-2236 (domestic) or 303-590-3000 (international). The passcode
is 11058413#.

   About Myogen

   Myogen has two product candidates in late-stage clinical
development: ambrisentan for the treatment of patients with pulmonary
arterial hypertension (PAH) and darusentan for the treatment of
patients with resistant hypertension. Myogen and GlaxoSmithKline have
entered into a global PAH partnership in which Myogen has marketing
and distribution rights to GlaxoSmithKline's Flolan (epoprostenol
sodium) in the United States for the treatment of PAH and
GlaxoSmithKline has licensed ambrisentan from Myogen for all
territories outside of the United States. Myogen also conducts a
target and drug discovery research program focused on the development
of disease-modifying drugs for the treatment of chronic heart failure
and related cardiovascular disorders. Please visit Myogen's website at
www.myogen.com.

   Safe Harbor Statement

   The 2006 first quarter results press release and conference call
will contain forward-looking statements that involve significant risks
and uncertainties, including those that can be found in the "Risk
Factors" section of Myogen's Form 10-K for the year ended December 31,
2005 and in Myogen's periodic reports on Form 10-Q and Form 8-K.
Myogen is providing the information contained in the release and
conference call as of the date of the release and does not undertake
any obligation to update any forward-looking statements as a result of
new information, future events or otherwise. The company cautions
investors not to place undue reliance on the forward-looking
statements contained in the press release or the conference call. No
forward-looking statement can be guaranteed and actual events and
results may differ materially from those projected.